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ILLUSTRATIVE CASE
Sarah, a 2-year-old who has been vomiting 
and had diarrhea for the past 2 days, is 
brought to your offi ce by her parents. They 
tell you she’s unable to tolerate oral fl uids, 
and vomited twice after being given small 
amounts of juice and soup earlier in the day. 
Sarah has decreased urine output, but she 
is not febrile and has no blood in her stools. 
On examination, you fi nd mild tachycardia, 
dry mucous membranes, delayed capillary 
refi ll, and normal mental status.
 You try giving Sarah an oral electrolyte 
solution, but she vomits immediately. Her 
parents are reluctant to take her to the 
emergency department for intravenous 
(IV) hydration, and ask if you can provide a 
safe and effective alternative. 
Each year in the United States, pe-diatric gastroenteritis and dehy-dration are responsible for ap-
proximately 1.5 million outpatient visits2 
and 150,000 to 170,000 hospital admis-
sions.3 Oral hydration, recommended by 
pediatric practice guidelines2,4 and the 
World Health Organization,5 is safe and 
generally effective. But, as in Sarah’s case, 
emesis frequently interferes, leading to 
hospital admission for IV hydration.
❚  An antiemetic with 
fewer adverse effects 
Older antiemetic medications, such as 
promethazine, prochlorperazine, and 
metoclopramide, can cause sedation and 
extrapyramidal reactions. Ondansetron, 
a selective 5-hydroxytryptamine (5-HT3) 
receptor antagonist that has been used 
to control postoperative and chemo-
therapy-associated nausea and vomiting 
in children and adults, does not cause ei-
ther problem. In recent studies of ondan-
setron’s effectiveness in treating children 
Give oral ondansetron to chil-
dren with acute gastroenteritis 
and moderate dehydration 
who are unable to tolerate 
oral rehydration to reduce 
the vomiting and avoid the 
need for intravenous (IV) 
hydration or hospitalization.1 
Strength of recommendation 
A: Meta-analysis of 6 high-quality studies
DeCamp LS, Byerley JS, Doshi N, et al. Use of 
antiemetic agents in acute gastroenteritis, a sys-
tematic review and meta-analysis. Arch Pediatr 
Adolesc Med. 2008;162:858-865.
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the sedating and 
extrapyramidal 
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with gastroenteritis, increased diarrhea, 
lasting up to 48 hours after administra-
tion, was the only adverse event.1
Two earlier systematic reviews—a 
meta-analysis by Szajewska et al6 and a 
Cochrane review7—found clinical bene-
fi ts of ondansetron for vomiting associ-
ated with acute gastroenteritis. But both 
concluded that the evidence was insuf-
fi cient to recommend routine use of this 
drug. The meta-analysis that we review 
below included additional studies, and 
the researchers reached a different con-
clusion.
STUDY SUMMARY
❚  Antiemetic decreases 
vomiting, hospitalization
DeCamp et al conducted a systematic re-
view and meta-analysis of 11 prospective 
controlled trials that evaluated antiemet-
ic use in children with vomiting from 
acute gastroenteritis.1 Six of the 11 trials 
focused on ondansetron;8-13 these 6 were 
the most recently published and of the 
highest quality. (The researchers found 
the remaining 5 trials to be of low meth-
odological quality, with small sample siz-
es and inconsistent results, and concluded 
that the antiemetics they assessed should 
not be used for outpatients with gastro-
enteritis.) Their meta-analysis of these 6 
trials is the focus of this PURL. 
The ondansetron studies included a 
total of 745 children with vomiting and 
a clinical diagnosis of gastroenteritis. In 5 
of the trials, patients received only 1 dose 
of ondansetron;8-10,12,13 in the sixth, fami-
lies received additional doses of ondanse-
tron to use at home.11 In 3 trials, patients 
were given oral ondansetron—a tablet 
placed on the tongue that dissolves in 
minutes. The remaining 3 used an IV for-
mulation.8,10,13 Five trials were conducted 
in emergency departments (EDs),9-13 and 
1 in an inpatient setting.8 
Big reductions. Children who re-
ceived ondansetron had signifi cantly 
less vomiting (16.9% vs 37.8%) and IV 
fl uid administration (13.9% vs 33.9%), 
and fewer hospital admissions (7.5% 
vs 14.6%) compared with patients who 
were given a placebo (TABLE). Diarrhea, 
the only adverse event to be systemati-
cally evaluated, was assessed in all but 1 
of the trials.8-12 In 3 of the 5 that reported 
on this side effect, patients who received 
ondansetron had an increase in diarrhea 
for up to 48 hours.8,11,12
WHAT’S NEW
❚  Support for a strategy 
increasingly used in EDs
Physicians are just beginning to adopt 
the use of ondansetron as a strategy for 
avoiding IV hydration and hospitaliza-
tion for children with vomiting associ-
ated with minor gastrointestinal illness. 
As an adjunct to our report on this meta-
analysis, we analyzed the use of the anti-
emetic in children between the ages of 1 
and 10 years in emergency visits report-
ed to the National Ambulatory Medi-
cal Care Survey database from 2002 to 
2006. Among an estimate of more than 
3 million pediatric visits to EDs for acute 
PURLs methodology
This study was selected and 
evaluated using FPIN’s Priority 
Updates from the Research 
Literature (PURL) Surveillance 
System methodology. The 
criteria and ﬁ ndings leading to 
the selection of this study as 
a PURL can be accessed at 
www.jfponline.com/purls. 
The increase 
in diarrhea 
associated 
with ondansetron 
resolved in 48 
hours. 
Ondansetron reduces vomiting, hospitalization, and IV ﬂ uid use
TOTAL NUMBER OF PATIENTS
(N=745) ONDANSETRON PLACEBO RR (95% CI) NNT (95% CI)
Continued vomiting (n=659) 16.9% 37.8% 0.45 (0.33-0.62) 5 (4-7)
IV ﬂ uid administration (n=489) 13.9% 33.9% 0.41 (0.28-0.62) 5 (4-8) 
Hospital admission (n=662) 7.5% 14.6% 0.52 (0.27-0.95) 14 (9-44)
CI, confi dence interval; IV, intravenous; NNT, number needed to treat; RR, relative risk. 
Source: DeCamp LS, et al. Arch Pediatr Adolesc Med.1
TABLE
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gastroenteritis in each of these years, in 
2002 only 0.53% were treated with on-
dansetron. By 2006, that percentage had 
risen to 6.43%. 
A similar analysis of both ED and 
outpatient visits to academic medical 
centers and teaching hospitals from 2005 
through 2008 (estimated using data 
through October 2008), derived from 
the University Health System Consor-
tium Clinical Database, showed a simi-
lar trend. In 2005, only 0.5% of children 
presenting to EDs and 0.5% of those 
seeking outpatient care for acute gastritis 
received ondansetron. By 2008, the num-
bers had grown to an estimated 3.43% 
and 3.60%, respectively.
Given the positive results of the 
DeCamp study and the fact that oral on-
dansetron is now available in a generic 
formulation, we expect the use of this 
antiemetic to increase in both outpatient 
and emergency settings. We think quite a 
few IV lines and hospitalizations could 
be avoided with the use of this antiemet-
ic, not to mention the symptomatic relief 
for children. 
CAVEATS 
❚  Studies didn’t look at 
milder cases, primary care
None of the studies of oral ondansetron 
for acute gastroenteritis involved outpa-
tient settings, and all 6 of the trials fea-
tured children who were moderately ill. 
It has not yet been determined whether 
the benefi ts seen in the ED will apply 
to an ambulatory population in which 
many potential candidates for ondanse-
tron have milder gastroenteritis. Nor is 
it clear whether oral ondansetron would 
complement oral rehydration in primary 
care practices. More detailed evaluation 
of the reduction of vomiting at home 
over the course of the illness would help 
to answer these questions. 
Nonetheless, ondansetron appears 
to be safe. Increased diarrhea, the only 
documented side effect, resolved after 
48 hours, and did not appear to result in 
higher health care utilization. 
Don’t prescribe over the phone. It is im-
portant to note that all the ondansetron 
trials included an evaluation of each pa-
tient to consider other etiologies, such as 
central nervous system disorders or toxic 
exposures, prior to treatment. Physicians 
are cautioned not to prescribe antiemet-
ics over the telephone—or without fi rst 
ruling out more serious illnesses in which 
vomiting is part of the presentation. 
Studies were funded by pharma. The 
primary studies of ondansetron were 
funded by GlaxoSmithKline, the pharma-
ceutical company that manufactures the 
drug under the trade name Zofran. The 
authors of the meta-analysis reviewed the 
Clinical Trials Registry and the reference 
lists of the articles and contacted other 
experts to fi nd any unreported trials, but 
found no evidence of negative publica-
tion bias. Therefore, we have confi dence 
in these fi ndings. Ideally, additional studies 
will be conducted without drug company 
support, in an outpatient setting, to clarify 
the use of ondansetron as an adjunct to 
oral rehydration. 
CHALLENGES TO IMPLEMENTATION
❚ No major barriers 
Cost should not be a barrier to the use of 
oral ondansetron. The generic formula-
tion sells for $10 to $20 per tablet, and is 
covered by most health insurers. Howev-
er, treatment of children with acute gas-
troenteritis and moderate dehydration 
in the offi ce setting would likely require 
a period of observation for tolerance of 
oral rehydration before and after admin-
istration of ondansetron. This may be im-
practical in some busy clinics. ■
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Before giving 
an antiemetic 
to a child who 
appears to have 
gastroenteritis, it 
is essential to rule 
out more serious 
conditions. 
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